List view / Grid view
4 October 2016 | By Cisbio
Rapid advancements have been made in understanding the key role epigenetic modifications play in regulating cell activity and their implications on cell health and disease progression...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Epigenetics-based research tools company Active Motif has entered into adevelopment partnership with Swift Biosciences, a next generation sequencing...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
14 March 2016 | By Victoria White
Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, has appointed Dr Geoff Smith as CEO...
23 February 2016 | By Victoria White
Given the key role of epigenetics in all tumour types, Desktop Genetics' research has wide potential applications across all histological types of cancer...
22 September 2015 | By Victoria White
The companies have applied a crowdsourcing approach to establish a research team who will endeavour to identify new approaches for the treatment of patients with COPD...
6 May 2015 | By Victoria White
Gilead Sciences has acquired EpiTherapeutics, a scientific leader in the field of epigenetics with a library of first-in-class inhibitors, for $65 million.
28 April 2015 | By Victoria White
A new function now described for the protein dDsk2 links ubiquitin receptors for the first time with the regulation of gene expression...
12 January 2015 | By Oryzon
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015...
16 September 2014 | By Andrew Lloyd & Associates
Curie-Cancer and Inventiva announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR...
7 May 2014 | By Kevin V. Morris, Bhupinder Bhullar
In this Genomics In-Depth Focus: Kevin V. Morris discusses the therapeutic potential of RNA directed epigenetic regulation of transcription, and Bhupinder Bhullar looks at drug resistance mechanisms and target selection in disease treatment strategies...
